Over 110 Texas Auctions End Tomorrow 09/24 - Bid Now
Over 2300 Total Lots Up For Auction at Five Locations - FL 09/28, OK 09/29, NJ Cleansweep 09/30, CA 10/01, NJ 10/05

Rakuten and Shimadzu partner on a medical device to be used with the Illuminox platform

Press releases may be edited for formatting or style | June 18, 2021 Business Affairs


About Shimadzu Corporation
With "Contributing to Society through Science and Technology" as the corporate philosophy and "Realizing Our Wishes for the Well-being of Mankind and the Earth" as the management principle, Shimadzu Corporation operates in various fields such as testing and measuring instruments, medical systems, aircraft equipment, and industrial machinery and equipment. For the development of photoimmunotherapy, Shimadzu has also signed joint development agreements with the National Cancer Institute and the National Cancer Center Hospital East to advance the development of measurement technologies for photoimmunotherapy.

Servicing GE, Philips and Siemens CT equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

About Illuminox™ Platform
The Illuminox platform is an investigational platform based on a cancer therapy called photoimmunotherapy, which was developed by Dr. Hisataka Kobayashi and team from the National Cancer Institute in the United States. Rakuten Medical is developing the Illuminox platform as a technology consisting of a drug, device and other related components. The drug component of the platform consists of a targeting moiety conjugated with one or more dyes leading to selective cell surface binding. The device component consists of a light source that locally illuminates the targeted cells with non-thermal light to transiently activate the drug. Pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on Illuminox may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted cells and/or the removal of immunosuppressive elements within the microenvironment. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority.

Back to HCB News

You Must Be Logged In To Post A Comment